Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Pembrolizumab bij patiënten met NSCLC en performance status 2
mei 2020 | Immuuntherapie, Longoncologie